|
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Helsinn Therapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - Adaptive Biotechnologies (I); Juno/Celgene (I) |
Stock and Other Ownership Interests - Juno/Celgene (I) |